Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $24.72 Consensus Target Price from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average rating of “Hold” by the twenty-one brokerages that are presently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $24.7222.

A number of brokerages have weighed in on SRPT. Piper Sandler lowered their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research report on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, July 9th. Finally, Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, July 20th.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $14.86 on Thursday. The company has a market cap of $1.57 billion, a PE ratio of -15.48, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21. The firm has a 50-day moving average of $16.99 and a 200-day moving average of $18.69. Sarepta Therapeutics has a one year low of $14.68 and a one year high of $25.32. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.15 million. During the same period in the prior year, the firm earned ($3.42) EPS. Sarepta Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts forecast that Sarepta Therapeutics will post 3.89 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in Sarepta Therapeutics in the 4th quarter valued at about $25,000. iSAM Funds UK Ltd acquired a new stake in Sarepta Therapeutics during the third quarter worth approximately $25,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the period. Allworth Financial LP boosted its holdings in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the period. Finally, Larson Financial Group LLC grew its position in shares of Sarepta Therapeutics by 82.5% in the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 851 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.